My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2018-038A
CBCC
>
Official Documents
>
2010's
>
2018
>
2018-038A
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
12/21/2020 12:43:43 PM
Creation date
3/15/2018 11:23:59 AM
Metadata
Fields
Template:
Official Documents
Official Document Type
Agreement
Approved Date
02/20/2018
Control Number
2018-038A
Agenda Item Number
8.S.
Entity Name
Johnson-Davis, Inc.
Subject
Culvert Replacement
Area
74th Avenue and 1st Street SW
Project Number
1737
Bid Number
2018024
Jump to thumbnail
< previous set
next set >
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
211
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
4) Follow -Up Testing: Employees who in the course of their employment <br />enter an employee assistance program for drug-related problems or a drug <br />rehabilitation program, will submit to follow-up drug tests, unless they <br />voluntarily entered the program. When employees voluntarily enter a <br />program, the Company has the option to not require follow-up testing. If <br />follow-up testing is required, it will be conducted at least once a year for a 2 - <br />year period after completion of the program. Advance notice of a follow-up <br />testing date will not be given to the employee to be tested. <br />5) Random Testing: Employees may be required to submit to random, <br />unannounced testing that is spread reasonably throughout the calendar year. <br />Upon being notified of being selected for testing, an employee shall <br />immediately report to the test site. Employees shall be selected for random <br />testing using a scientifically valid method, which will provide each employee <br />with an equal chance of being tested each time selections are made. <br />6) Additional Testing: Employees may be subject to additional testing. as <br />required by applicable state and federal laws, rules or regulations or as deemed <br />necessary by the Company. The Company may, at its discretion, conduct drug <br />- testing at any time. <br />ADDITIONAL INFORMATION <br />Confidi_hhfiality: Employers and their agents and laboratories must keep. drug test <br />------------- <br />results and other related information confidential. if information is released, it shall <br />be done solely under a written consent form voluntarily signed by the person tested <br />unless a release is compelled by a hearing officer or a court or unless it is deemed <br />appropriate by a professional occupational licensing board in a related disciplinary <br />proceeding. The consent form must meet the criteria set by the State of Florida and <br />in accordance with Florida Statutes § 440.102(8). <br />Reporting Use of Prescription or Non -Prescription Medications: An <br />employee/job applicant can confidentially report the use of all prescription or non- <br />prescription medications to a medical review officer, both before and after being <br />tested, as presence of those medications in the body may affect the outcome of the <br />test. A list of the most common medications by brand name, common name and by <br />chemical name, which may alter or affect a drug test, is listed on Attachment DFW-4. <br />Employee Suspension: The Company may suspend employees without pay pending <br />the results of a drug test or investigation.. <br />
The URL can be used to link to this page
Your browser does not support the video tag.